Helix BioPharma Corp. (HBP) - Total Liabilities
Based on the latest financial reports, Helix BioPharma Corp. (HBP) has total liabilities worth CA$3.00 Million CAD (≈ $2.17 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Helix BioPharma Corp. to assess how effectively this company generates cash.
Helix BioPharma Corp. - Total Liabilities Trend (2007–2025)
This chart illustrates how Helix BioPharma Corp.'s total liabilities have evolved over time, based on quarterly financial data. See HBP net assets for net asset value and shareholders' equity analysis.
Helix BioPharma Corp. Competitors by Total Liabilities
The table below lists competitors of Helix BioPharma Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cystech Electronics Corp
TWO:6651
|
Taiwan | NT$352.87 Million |
|
Centrica PLC
LSE:CNA
|
UK | GBX11.92 Billion |
|
Able Global Bhd
KLSE:7167
|
Malaysia | RM259.17 Million |
|
Biosyent Inc.
V:RX
|
Canada | CA$7.88 Million |
|
American Outdoor Brands Inc
NASDAQ:AOUT
|
USA | $70.52 Million |
|
Dardanel Onentas Gida Sanayi AS
IS:DARDL
|
Turkey | TL446.32 Million |
|
Allied Tecnologia S.A
SA:ALLD3
|
Brazil | R$2.08 Billion |
|
Faze Three Limited
NSE:FAZE3Q
|
India | Rs3.29 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Helix BioPharma Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Helix BioPharma Corp. (HBP) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Helix BioPharma Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Helix BioPharma Corp. (2007–2025)
The table below shows the annual total liabilities of Helix BioPharma Corp. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$3.22 Million ≈ $2.33 Million |
+103.67% |
| 2024-07-31 | CA$1.58 Million ≈ $1.14 Million |
-15.70% |
| 2023-07-31 | CA$1.87 Million ≈ $1.35 Million |
-45.09% |
| 2022-07-31 | CA$3.41 Million ≈ $2.47 Million |
-37.50% |
| 2021-07-31 | CA$5.46 Million ≈ $3.95 Million |
+183.53% |
| 2020-07-31 | CA$1.93 Million ≈ $1.39 Million |
-54.39% |
| 2019-07-31 | CA$4.22 Million ≈ $3.05 Million |
+57.85% |
| 2018-07-31 | CA$2.67 Million ≈ $1.93 Million |
+21.32% |
| 2017-07-31 | CA$2.20 Million ≈ $1.59 Million |
+69.02% |
| 2016-07-31 | CA$1.30 Million ≈ $943.29K |
+34.57% |
| 2015-07-31 | CA$969.00K ≈ $700.96K |
-7.01% |
| 2014-07-31 | CA$1.04 Million ≈ $753.77K |
+9.92% |
| 2013-07-31 | CA$948.00K ≈ $685.77K |
-31.90% |
| 2012-07-31 | CA$1.39 Million ≈ $1.01 Million |
-38.35% |
| 2011-07-31 | CA$2.26 Million ≈ $1.63 Million |
-4.04% |
| 2010-07-31 | CA$2.35 Million ≈ $1.70 Million |
+4.30% |
| 2009-07-31 | CA$2.26 Million ≈ $1.63 Million |
+97.20% |
| 2008-07-31 | CA$1.14 Million ≈ $827.55K |
-25.67% |
| 2007-07-31 | CA$1.54 Million ≈ $1.11 Million |
-- |
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more